ArticleJournal of fluorescence2026
Developing an Isoflavone-derived Fluorescent Probe for Monitoring Cytochrome P450 1A1 and Imaging in Living Colorectal Cancer Cells.
Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this work, a fluorescent probe, ISOF-CYP, derived from the typical isoflavone formonetin was developed for monitoring the cytochrome P450 1A1 (CYP1A1) level and imaging in living colorectal cancer cells. Under the excitation at 370 nm, ISOF-CYP acted as the specific substrate of CYP1A1 to report the notable fluorescence signal at 495 nm. During the investigations on the testing conditions, ISOF-CYP exhibited the beneficial performances including a rapid response within 20 min, a high and stable intensity in pH 6.0–9.0, 35–40 ℃. The fluorescence intensity of ISOF-CYP exhibited a dose-dependent enhancement along with the increase of the CYP1A1 level. The detection limit was determined as 0.095 nM from the linear regression. ISOF-CYP selectively detected CYP1A1 among the competing and accompanying analytes. With low cytotoxicity, ISOF-CYP achieved imaging the CYP1A1 level in living colorectal cancer cells. The imaging covered the situations affected by the reported drug, anesthetic protection, and combination strategy. This work inspired a typical natural product modification strategy for the pre-clinical diagnosis and therapeutical management.
Indexed as
Identifiers
41615649What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.